about
Economic instruments for obesity prevention: results of a scoping review and modified Delphi surveyBecoming the best mom that I can: women's experiences of managing depression during pregnancy--a qualitative studyThe impact of drug vintage on patient survival: a patient-level analysis using Quebec's provincial health plan data.Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence.Canada's laws on pharmaceutical intellectual property: the case for fundamental reform.Economic evaluation of vaccines in Canada: A systematic review.Effect of the Low Risk Ankle Rule on the frequency of radiography in children with ankle injuries.Cost Consequence Analysis of Implementing the Low Risk Ankle Rule in Emergency Departments.The effects of drug subsidies on out-of-pocket prescription drug expenditures by seniors: regional evidence from Canada.Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis.Does it matter whom and how you ask? inter- and intra-rater agreement in the Ontario Health Survey.The case for an essential medicines list for Canada.Impact of administrative restrictions on antibiotic use and expenditure in Ontario: time series analysis.Optimization of controlled release nanoparticle formulation of verapamil hydrochloride using artificial neural networks with genetic algorithm and response surface methodology.An empirical analysis of milk addiction.Impact of depression and recreational drug use on emergency department encounters and hospital admissions among people living with HIV in Ontario: A secondary analysis using the OHTN cohort study.A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study.The opportunity cost of capital: development of new pharmaceuticals.Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo studyValidation of a Prediction Model to Estimate Health Utilities Index Mark 3 Utility Scores from WOMAC Index Scores in Patients with Osteoarthritis of the HipEstimating the clinical cost of drug development for orphan versus non-orphan drugsA re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British ColumbiaProportion of osteoporotic post-menopausal women at increased risk for upper GI adverse events associated with bisphosphonate therapyHow should we support pharmaceutical innovation?Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literatureHow Effective Is the Medicare Part D Drug Plan?Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario
P50
Q26853174-87F3CCEB-FD40-44ED-89A8-B05200A0ADEAQ30834231-19C75069-ED43-4B38-9556-C41650020383Q33458889-F37B60EE-D1DF-4A75-A96D-2BCBA4E9A8FCQ35747442-1C2F52DD-BFA5-4501-90F2-4E0F64D8D213Q35839460-552CC78B-1C6A-4536-AB55-0484061FA4F6Q37131005-9E49A502-2F24-4C4B-9D9C-A071CE7B66CAQ37229731-4AC6E7E7-3A52-4A7B-91A4-B3A62AF52B7EQ40722936-F462BD0B-AABD-4C23-AA2A-BD440228E2D3Q42684300-CD046C1F-0F89-4225-B9F1-B246B532A4DFQ44953857-4F1C29A7-303C-4B83-B912-A69B629BE887Q45184965-90A3F34E-CFE0-42C5-809C-AA44F4DCA28AQ45874109-4A5A365F-5E83-4286-B1E8-927E29BBECAFQ46868800-39F187B4-AE67-4EFC-AC62-EB5AD8A41505Q50912276-83281971-EBE5-40F5-859B-B0FF4998316CQ52286821-6133405B-6532-4513-BFFF-C2080EE0A80CQ52598809-A2252EA0-452A-4400-8FD5-DAFD9DAED94AQ53004091-4D574D50-B5D3-489A-85F3-C1D7D665FEF1Q53171888-8F7D17D0-78F4-4E13-8DAB-36444919757AQ57266829-7A67D3AC-2B02-4853-9637-EA1D5E46E669Q57759177-80F2820C-35D9-4079-8606-0928B4070456Q60912792-E9AF1D53-D4C4-4560-BACC-99FDF8A46F29Q82650297-F240FF2C-0972-4E46-83B2-0B7EE0DEE252Q82691172-69E3B997-8E80-49DD-9007-BBE2CB3DBB3DQ84386166-F42583B4-428B-4E53-89CE-08DDE6DF0E5EQ84386184-0A58FC4C-63DA-45E3-8017-C74A3DCC417DQ85379787-FDA22145-C78D-4F19-8A49-ADE60ADA9990Q90438332-C9FD8305-2CFA-4C02-A00E-D8B1063AED38
P50
description
researcher ORCID ID = 0000-0003-1978-2834
@en
name
Paul Grootendorst
@ast
Paul Grootendorst
@en
Paul Grootendorst
@es
Paul Grootendorst
@nl
type
label
Paul Grootendorst
@ast
Paul Grootendorst
@en
Paul Grootendorst
@es
Paul Grootendorst
@nl
prefLabel
Paul Grootendorst
@ast
Paul Grootendorst
@en
Paul Grootendorst
@es
Paul Grootendorst
@nl
P31
P496
0000-0003-1978-2834